Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin

British Journal of Ophthalmology

Volumn 84, Issue 7, 2000, Pages 788-790

  Hardus, P ^a   Verduin, W M ^b   Postma, G ^b   Stilma, J S ^a,b   Berendschot, T T J M ^b   Van Veelen, C W M ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; VIGABATRIN;

ARTICLE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TEMPORAL LOBE EPILEPSY; VISUAL FIELD; VISUAL FIELD DEFECT;

ANTICONVULSANTS; EPILEPSY, TEMPORAL LOBE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; PERIMETRY; STATISTICS, NONPARAMETRIC; VIGABATRIN; VISUAL FIELDS;

EID: 0033920549     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.84.7.788     Document Type: Article

References (20)

1. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997;314:180-1.
2. Blackwell N, Hayllar J, Kelly G. Severe persistent visual field constrictions associated with vigabatrin. BMJ 1997;314:1994.
3. Wong IC, Mawer GE, Sander JW, Severe persistent visual field constrictions associated with vigabatrin. BMJ 1997; 314:1693-4.
4. Wilson EA, Brodie MJ. Severe persistent persistent visual field constrictions associated with vigabatrin. BMJ 1997; 314:1993.
5. Mackenzie R, Klistorner A. Asymptomatic as well as symptomatic defects occur with vigabatrin. BMJ 1997;316:233.
6. Kraemer G, Scollo-Lavizarri G, Jallon P, et al. Vigabatrin associated bilateral concentric visual field defects in four patients. Epilepsia 1997;38 (suppl 8):179.
7. Krauss GL, Johnson MA, Miller NR. Vigabatrin associated retinal cone system dysfunction. Neurology 1998;50:614-8.
8. Harding G, Wild J, Robertson K, et al. Electrooculography, ERGs, multifocal ERGs and VEPs in epileptic patients showing visual field disorders. Electroenceph Clin Neurophysiol 1997;103:96 (P13-14).
9. Rao GP, Ah Fat F3 Kyle D, et al. Study is needed of visual field associated with any long term antiepileptic drug. BMJ 1998;317:206.
10. Daneshvar H, Racette L, Coupland SG, et al. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999;106:1792-11.
11. Lawden MC, Eke T, Degg C, et al. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 1999;67:716-22.
12. Wild JM, Martinez C, Reinshagen G, et al. Characteristics of a unique visual field defect attributed to vigabatrin, Epilepsia 1999;40:1784-94.
13. Hardus P, Verduin WM, Postma G, et al. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin. Epilepsia (in press).
14. Esterman B. Grids for functional scoring of visual fields. Doc Ophthal Proc Series Vol 26. Greve EL, Verriest G, eds.
15. American Medical Association. Guides to the evaluation of permanent impairment. 8/213, 4th ed, San Francisco: AMA, 1993.
16. Harding GFA. Severe persistent visual field constriction associated with vigabatrin. BMJ 1998;316:322.
17. Versino M, Veggiotti P. Reversibility of vigabatrin-induced visual-field defect. Lancet 1999;354:486.
18. Stewart JGE Automated perimetry and malingerers. Ophthalmology 1995;102:27-32.
19. Thompson JC, Kosmorsky GS, Ellis BD. Fields of dreamers and dreamed-up fields. Ophthalmology 1996;103:117-25.
20. Trauzettel-Klosinski S. Untersuchungsstrategien bei Simulation und funktionellen Sehstörungen. Klin Monatsbl Augenheilkd 1997;211:73-83.